Verge Genomics

Verge Genomics

Develops drugs using human genomics and AI

About Verge Genomics

Simplify's Rating
Why Verge Genomics is rated
A
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A+ on Rating Differentiation

Industries

AI & Machine Learning

Biotechnology

Company Size

51-200

Company Stage

Series B

Total Funding

$130.5M

Headquarters

South San Francisco, California

Founded

2015

Overview

Verge Genomics develops drugs for severe diseases like ALS, Parkinson's Disease, and Frontotemporal Dementia using human genomics and machine learning. Instead of traditional animal models, they create a large database of human tissue to better understand disease causes. Their AI platform, CONVERGE®, helps analyze this data to identify potential drug candidates. Their first drug, VRG50635, is in clinical trials for ALS and was developed in just four years. Verge Genomics aims to provide effective treatments for patients and generate revenue through the commercialization of their drug candidates.

YC Company
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnerships with Stem Pharm and Emerald Innovations enhance drug development and trial accuracy.
  • AI-driven platform enables rapid progression of drug candidates, exemplified by VRG50635's clinical entry.
  • Integration of digital biosensors in trials provides comprehensive data on drug efficacy and patient health.

What critics are saying

  • Competition from companies like Eli Lilly could impact Verge's market share and innovation lead.
  • Reliance on digital devices in trials may pose risks if data accuracy is compromised.
  • Proof-of-concept study for VRG50635 carries risk of unforeseen side effects or lack of efficacy.

What makes Verge Genomics unique

  • Verge Genomics uses AI and human genomics for drug discovery, unlike traditional methods.
  • Their CONVERGE® platform accelerates drug development, moving candidates to trials in four years.
  • They focus on neurodegenerative diseases, using a large proprietary multi-omics database for insights.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$130.5M

Above

Industry Average

Funded Over

3 Rounds

Notable Investors:
Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Above Average

Industry standards

$35M
$45M
Linktree
$65M
Substack
$98M
Verge Genomics
$100M
ClickUp

Benefits

Excellent medical, dental, and vision coverage

401(k) plan with employer matching for contributions

Disability insurance, Life insurance, Dependant Care FSA and Healthcare FSA

Unlimited paid time off

Paid parental leave

Access to free onsite fitness center

Free snacks and lunch for employees who work onsite

WFH stipend for employees who work remotely

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

3%

2 year growth

3%
Labiotech
Jan 22nd, 2025
Curing Als? Thirteen Companies Developing New Treatments In 2025

Newsletter Signup - Under Article / In Page"*" indicates required fields Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to the loss of muscle control. As motor neurons deteriorate, patients experience muscle weakness, paralysis, and eventually respiratory failure. The exact cause of ALS remains unknown, and currently, there is no cure.The treatment options for ALS are limited, focusing primarily on slowing disease progression and managing symptoms. The treatment landscape for ALS has only seen modest advancements over the past few decades.Approved in 1995, Riluzole modestly prolongs survival in ALS patients by reducing the release of glutamate, a neurotransmitter that can be toxic to motor neurons at high levels. An important advancement in the field has to be tofersen’s approval by the U.S. Food and Drug Administration (FDA) in 2023 which was a significant step forward in personalized treatment for ALS.The lack of treatment options finds its explanation in a particularly challenging disease area

The Tokenist
Nov 20th, 2024
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs

Verge Genomics and Eli Lilly (NYSE: LLY) have announced significant progress in their joint efforts to develop novel treatments for amyotrophic lateral sclerosis (ALS), a debilitating neurodegenerative disease.

Labiotech
Jul 11th, 2024
Five Bioinformatics Companies Making Waves In The Biopharma Industry In 2024

Bioinformatics is a field of science that integrates computer technology to analyze biological data, particularly DNA and protein sequences, to advance therapies and boost healthcare research. In this article, we take a look at five companies at the top of their bioinformatics game in 2024.SynthaceBritish-American life science company Synthace’s DNA Assembly platform allows people to import assembly design files at the start of the workflow, after which, it helps create the plasmids – circular DNA molecules found in microbes – that are required for projects.Once customers specify what kind of plasmid they want designed, Synthace’s platform calculates the liquid movements, concentrations, and dilutions needed throughout the entire process. The company helps estimate reagent volumes as well as automation instructions for customers to be able to run experiments without having to use spreadsheets or any kind of programming. With a focus on molecular biology, the bioinformatics company aids scientists in planning and automating processes like DNA assembly for their research and development (RD) projects.Synthace has previously worked with tech giants like Microsoft to design manufacturing processes for lentiviral vectors to be able to program cells to discover new medicines. It has also collaborated with global biopharma Ipsen to develop medicines to treat rare diseases and pain relief.  The company has also been known to use OpenAI’s ChatGPT to design complex experiments.Last year, Synthace was among 50 companies like Google, mental healthcare company Headspace, and food company Beyond Meat, to win the international Impact Fifty award recognizing the most impactful companies to work for.Verge GenomicsImmersed in the drug discovery space, Verge Genomics leverages artificial intelligence (AI) to discover and develop drugs. Its CONVERGE discovery platform is a closed-loop machine learning system that combines genomics and computational tools to scout for drug targets and predict how well investigational medicines could perform in the clinic.This way, it looks to develop drugs at a faster rate. In its pipeline, Verge has an amyotrophic lateral sclerosis (ALS) drug undergoing proof-of-concept studies. ALS is a fatal motor neuron disease that affects the nerve cells in the spinal cord and brain

Ashland Town News
Jan 9th, 2024
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) - Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS).

BioSpace
Jan 9th, 2024
Verge Genomics Announces Initiation Of Proof-Of-Concept Study For The Treatment Of Amyotrophic Lateral Sclerosis (Als) With Vrg50635

VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platformVerge’s proof-of-concept study uses first-of-its-kind, cutting-edge design and technology to deliver more precise and comprehensive insights into how VRG50635 may benefit individuals with ALS“I applaud Verge for creating a bold proof-of-concept design that incorporates cutting-edge technology and scientific innovation in their efforts to create groundbreaking therapies for ALS.” - Dr. Angela Genge, Director, ALS Centre of Excellence for Research and Patient Care, Montreal Neurological Institute-Hospital SOUTH SAN FRANCISCO, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The study will assess the safety and tolerability of escalating doses of VRG50635, a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform. VRG50635 is one of the first drugs to enter the clinic that was entirely discovered and developed from an AI-enabled platform.In traditional ALS clinical trials, a patient's progress is measured in a clinical setting using poorly responsive physician rating scales, which typically provide sparse data to establish proof of concept early in clinical development. In contrast, Verge's study harnesses the power of digital devices to collect thousands of objective, quantitative, relevant measurements directly from the patient, including mobility, breathing, and sleeping all from the comfort of their home

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Verge Genomics right now.

Find jobs on Simplify and start your career today

💡
We update Verge Genomics's jobs every 8 hours, so check again soon! Browse all jobs →